Advanced Filters
noise

non-small-cell-lung-cancer Clinical Trials

A listing of non-small-cell-lung-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,203 clinical trials
T T.Jeroen Hiltermann, MD

Clinical Validation and Benchmarking of Top PerformingctDNA Diagnostics - Stage III NSCLC

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, …

18 years of age All Phase N/A
G Guibin Qiao, MD

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate …

18 - 80 years of age All Phase N/A
W Wu yilong, phD

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed …

18 years of age All Phase N/A
I Ian Daniels

Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device. The primary objective of the study is to assess whether significant changes in DNA mutation …

18 - 99 years of age All Phase N/A
C Clinical Trials Nurse Navigator

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.

18 years of age All Phase N/A
E Emilio Bria, Professor

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed overview of resistance mechanisms and clinical outcomes according to current standard treatments.

18 years of age All Phase N/A
H Haichuan Su, PhD

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M mutation positive NSCLC. This study aims to investigate the efficacy and safety of furmonertinib in the …

18 years of age All Phase N/A

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.

18 - 80 years of age All Phase N/A
J Jair Bar, MD-PhD

Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

Neoadjuvant chemo-immunotherapy, with or without adjuvant immunotherapy, is currently the standard of care for resectable stage II-III NSCLC. One of the major drawbacks of neoadjuvant treatment is the risk of surgery cancellation. In most of the studies including a neoadjuvant component of treatment, about 20% of recruited patients do not …

18 years of age All Phase N/A
S Sandy Tran

Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD

This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history of substance abuse or alcohol use impacts care for non-small cell lung cancer.

18 years of age All Phase N/A

Simplify language using AI